251 related articles for article (PubMed ID: 17451235)
21. Discovery of pyrrolopyrimidine inhibitors of Akt.
Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
[TBL] [Abstract][Full Text] [Related]
22. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.
Caldwell JJ; Davies TG; Donald A; McHardy T; Rowlands MG; Aherne GW; Hunter LK; Taylor K; Ruddle R; Raynaud FI; Verdonk M; Workman P; Garrett MD; Collins I
J Med Chem; 2008 Apr; 51(7):2147-57. PubMed ID: 18345609
[TBL] [Abstract][Full Text] [Related]
23. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
[TBL] [Abstract][Full Text] [Related]
24. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
[TBL] [Abstract][Full Text] [Related]
25. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
26. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
[TBL] [Abstract][Full Text] [Related]
27. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
28. Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
Oyarzabal J; Zarich N; Albarran MI; Palacios I; Urbano-Cuadrado M; Mateos G; Reymundo I; Rabal O; Salgado A; Corrionero A; Fominaya J; Pastor J; Bischoff JR
J Med Chem; 2010 Sep; 53(18):6618-28. PubMed ID: 20722422
[TBL] [Abstract][Full Text] [Related]
29. Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model.
Bilodeau MT; Balitza AE; Hoffman JM; Manley PJ; Barnett SF; Defeo-Jones D; Haskell K; Jones RE; Leander K; Robinson RG; Smith AM; Huber HE; Hartman GD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3178-82. PubMed ID: 18479914
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, biological evaluation and docking studies of 4-amino-tetrahydroquinazolino[3,2-e]purine derivatives.
Verones V; Flouquet N; Farce A; Carato P; Leonce S; Pfeiffer B; Berthelot P; Lebegue N
Eur J Med Chem; 2010 Dec; 45(12):5678-84. PubMed ID: 20884092
[TBL] [Abstract][Full Text] [Related]
31. Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinases.
Xu G; Searle LL; Hughes TV; Beck AK; Connolly PJ; Abad MC; Neeper MP; Struble GT; Springer BA; Emanuel SL; Gruninger RH; Pandey N; Adams M; Moreno-Mazza S; Fuentes-Pesquera AR; Middleton SA; Greenberger LM
Bioorg Med Chem Lett; 2008 Jun; 18(12):3495-9. PubMed ID: 18508264
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.
Lin X; Murray JM; Rico AC; Wang MX; Chu DT; Zhou Y; Del Rosario M; Kaufman S; Ma S; Fang E; Crawford K; Jefferson AB
Bioorg Med Chem Lett; 2006 Aug; 16(16):4163-8. PubMed ID: 16765046
[TBL] [Abstract][Full Text] [Related]
33. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
34. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines.
Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K
J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448
[TBL] [Abstract][Full Text] [Related]
35. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
37. Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling.
Chao WR; Yean D; Amin K; Green C; Jong L
J Med Chem; 2007 Jul; 50(15):3412-5. PubMed ID: 17602463
[TBL] [Abstract][Full Text] [Related]
38. Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha.
Mills SJ; Komander D; Trusselle MN; Safrany ST; van Aalten DM; Potter BV
ACS Chem Biol; 2007 Apr; 2(4):242-6. PubMed ID: 17432822
[TBL] [Abstract][Full Text] [Related]
39. Structure-based optimization of novel azepane derivatives as PKB inhibitors.
Breitenlechner CB; Wegge T; Berillon L; Graul K; Marzenell K; Friebe WG; Thomas U; Schumacher R; Huber R; Engh RA; Masjost B
J Med Chem; 2004 Mar; 47(6):1375-90. PubMed ID: 14998327
[TBL] [Abstract][Full Text] [Related]
40. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]